News: Drug Discovery

Next Page »

VICC Investigators Earn Breast Cancer Grants

Thursday, October 23rd, 2014

Three Vanderbilt-Ingram Cancer Center (VICC) investigators have been awarded breast cancer research grants totaling $830,000 from the Susan G. Komen organization.

Study Creates New Road Map for Cell Activity

Thursday, September 4th, 2014

Human cells are constructed in large part from proteins whose activity can be altered by the incorporation of oxygen in what are known as redox modifications. Detecting these redox modifications as they occur in proteins is delicate work, “like trying to catch a fairy in a jar,” said Daniel Liebler, Ph.D., Ingram Professor of Cancer […]

Limiting Breast Cancer Metastasis

Thursday, August 28th, 2014

Targeting a cytokine pathway may offer a way to inhibit breast cancer cell survival and metastasis, study suggests.

Proteins May Point to Prostate Cancer Drug Targets

Tuesday, August 7th, 2012

Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. The findings, reported recently in the Journal of Clinical Investigation, point toward potential drug targets and prognostic markers for prostate cancer. “We […]

Uncommon BRAF Melanoma Mutation

Wednesday, July 18th, 2012

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center […]

New Cancer Drug Shows Promise

Thursday, July 12th, 2012

An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer centers tested the new compound. The results of the […]

Fesik’s Cancer Research Achievements Honored

Friday, March 30th, 2012

Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry at Vanderbilt, will receive the 2012 AACR Award for Outstanding Achievement in Chemistry in Cancer Research. Fesik, who holds the Orrin H. Ingram II chair in cancer research, will receive the special recognition during the American Association for Cancer Research (AACR) Annual Meeting in Chicago March […]

My Health Chat: Cancer Drug Discovery

Thursday, March 22nd, 2012

The April program for My Health Chat will be the promising world of cancer drug discovery. Panelists will be Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology, and Stephen Fesik, Ph.D., director of drug discovery at Vanderbilt-Ingram Cancer Center. They will be discussing and taking questions about how information about the genetic […]

Carroll Wins Vanderbilt’s First Damon Runyon Fellowship

Friday, January 27th, 2012

Mary Carroll, Ph.D., a postdoctoral research fellow in Biochemistry, was recently named one of 18 Damon Runyon Fellows by the Damon Runyon Cancer Research Foundation. The three-year, $156,000 award provides independent funding for outstanding postdoctoral scientists to pursue innovative projects. Carroll is the first postdoctoral fellow from Vanderbilt to receive this award. “I am honored […]

VUMC Teams with 3 Midstate Hospitals

Friday, September 23rd, 2011

Leaders of Vanderbilt University Medical Center, Maury Regional Medical Center, Northcrest Medical Center and Williamson Medical Center today announced affiliation agreements establishing a partnership between these medical centers to work collaboratively to create new jointly operated programs and services in the counties where these hospitals reside. These programs are intended to expand primary and specialty […]